Table 1 Clinical characteristics according to tertiles of mean rCUC
Total (N = 50) | T1 (mean rCUC < 11.7 L/week/1.73m2), n = 17 | T2 (mean rCUC 11.8–29.8 L/week/1.73m2), n = 17 | T3 (mean rCUC ≥ 29.9 L/week/1.73m2), n = 16 | P for trend | |
|---|---|---|---|---|---|
Male sex, n (%) | 37 (74.0) | 12 (70.6) | 11 (64.7) | 14 (87.5) | 0.277 |
Age, years | 54 ± 14 | 53 ± 14 | 55 ± 15 | 55 ± 15 | 0.499 |
Dialysis duration, months | 20.2 ± 11.6 | 23.4 ± 12.3 | 18.1 ± 9.7 | 18.8 ± 12.5 | 0.213 |
Original disease | |||||
DN, n (%) | 16 (32.0) | 7 (41.2) | 6 (35.3) | 3 (18.8) | 0.167 |
Non-DN, n (%) | 34 (68.0) | 10 (58.8) | 11 (64.7) | 13 (81.2) | |
Blood pressure, mmHg | |||||
Systolic | 139 ± 14 | 141 ± 11 | 137 ± 18 | 139 ± 13 | 0.845 |
Diastolic | 81 ± 11 | 82 ± 9 | 78 ± 16 | 82 ± 7 | 0.581 |
Daily alcohol consumption, n (%) | 20 (40.0) | 5 (29.4) | 8 (47.1) | 7 (43.8) | 0.394 |
Current smoker, n (%) | 9 (18.0) | 3 (17.7) | 2 (11.8) | 4 (25.0) | 0.593 |
Past histories of CVD, n (%) | 8 (16.0) | 2 (11.8) | 4 (23.5) | 2 (12.5) | 0.939 |
History of peritonitis, n (%) | 8 (16.0) | 1 (5.9) | 3 (17.7) | 4 (25.0) | 0.133 |
Body mass index, kg/m2 | 22.9 ± 2.9 | 22.4 ± 2.4 | 22.1 ± 2.7 | 24.2 ± 3.2 | 0.124 |
CTR, % | 48.2 ± 5.4 | 49.8 ± 4.7 | 48.3 ± 4.6 | 46.6 ± 6.7 | 0.075 |
Dialysis modality | |||||
APD, n (%) | 22 (44.0) | 11 (64.7) | 8 (47.1) | 9 (56.3) | 0.614 |
CAPD, n (%) | 28 (56.0) | 6 (35.3) | 9 (52.9) | 7 (43.7) | |
Use of icodextrin, n (%) | 41 (82.0) | 16 (94.1) | 13 (76.5) | 12 (75.0) | 0.150 |
Use of HG dialysate, n (%) | 17 (34.0) | 11 (64.7) | 4 (23.5) | 2 (12.5) | 0.002 |
Dose of ESA, μg/week | 34 ± 18 | 37 ± 16 | 32 ± 16 | 31 ± 23 | 0.206 |
Total Kt/V, /week | 1.71 ± 0.34 | 1.66 ± 0.42 | 1.61 ± 0.31 | 1.87 ± 0.23 | 0.011 |
Renal Kt/V, /week | 0.46 ± 0.37 | 0.10 ± 0.11 | 0.42 ± 0.18 | 0.88 ± 0.27 | < 0.001 |
Peritoneal Kt/V, /week | 1.25 ± 0.38 | 1.56 ± 0.41 | 1.19 ± 0.21 | 0.99 ± 0.22 | < 0.001 |
Renal Ccr, L/week, /week | 29.2 ± 26.9 | 5.1 ± 4.9 | 27.4 ± 8.9 | 56.8 ± 27.8 | < 0.001 |
Urine volume, L/day | 0.80 ± 0.64 | 0.22 ± 0.24 | 0.76 ± 0.38 | 1.44 ± 0.55 | < 0.001 |
Mean rCUC, L/week/1.73m2 | 22.7 ± 19.4 | 4.2 ± 4.2 | 20.5 ± 6.2 | 44.5 ± 16.5 | < 0.001 |
D/Pcr | 0.73 ± 0.16 | 0.76 ± 0.16 | 0.72 ± 0.17 | 0.70 ± 0.16 | 0.328 |
Prescriptions, n (%) | |||||
RAS inhibitors | 48 (96.0) | 17 (100.0) | 15 (88.2) | 16 (100) | 0.972 |
Calcium channel blockers | 37 (74.0) | 15 (88.2) | 10 (58.8) | 12 (75.0) | 0.370 |
β blockers | 23 (46.0) | 11 (64.7) | 6 (35.3) | 6 (37.5) | 0.113 |
Calcium-containing PBs | 44 (88.0) | 13 (76.5) | 16 (94.1) | 15 (93.8) | 0.123 |
Non-calcium containing PBs | 29 (58.0) | 14 (82.4) | 6 (35.3) | 9 (56.3) | 0.119 |
Iron preparations | 11 (22.5) | 7 (41.2) | 2 (11.8) | 2 (13.3) | 0.054 |
Vitamin D | 27 (54.0) | 9 (52.9) | 7 (41.2) | 11 (68.8) | 0.375 |
Cinacalcet hydrochloride | 4 (8.0) | 1 (5.9) | 1 (5.9) | 2 (12.5) | 0.488 |